Congjun Zhang
Overview
Explore the profile of Congjun Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang C, Li J, Wu H, Huang W, Da L, Shen Y, et al.
Front Pharmacol
. 2024 Feb;
15:1356013.
PMID: 38357311
Envafolimab, a PD-L1 inhibitor, has demonstrated potential in treating advanced malignant solid tumors (AMST). To study its' efficacy and safety in AMST, our retrospective study recruited 64 patients with various...
2.
Zhang M, Zhu S, Chen L, Wu Y, Ye Y, Wang G, et al.
Heliyon
. 2023 Aug;
9(8):e18499.
PMID: 37560685
The incidence of early-onset colorectal cancer (EO-CRC), diagnosed in patients younger than 50 years, has increased in incidence alarmingly over the past few decades, while overall incidence and mortality of...
3.
Hu X, Chen W, Li F, Ren P, Wu H, Zhang C, et al.
Front Oncol
. 2023 May;
13:1053125.
PMID: 37188174
Objective: To explore the altered expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and cell proliferation index (Ki-67) in primary and metastatic breast...
4.
Da L, Qu Z, Zhang C, Shen Y, Huang W, Zhang Y, et al.
Front Oncol
. 2023 Apr;
13:1144875.
PMID: 37035159
Purpose: This study aims to assess the prognostic value of inflammatory markers and clinical features in advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients receiving anti-programmed death 1 (PD-1)...
5.
Pan Z, Yu L, Shao M, Ma Y, Cheng Y, Wu Y, et al.
BMC Public Health
. 2023 Feb;
23(1):346.
PMID: 36797719
With the increasing severity of the malignant tumors situation worldwide, the impacts of climate on them are receiving increasing attention. In this study, for the first time, all-malignant tumors were...
6.
Huang W, Zhang Q, Da L, Shen Y, Xiong F, Zhang C
J Cancer Res Ther
. 2022 Jun;
18(2):576-580.
PMID: 35645130
Background: The role of camrelizumab combined with chemotherapy as the second-line therapy in nonsquamous nonsmall cell lung cancer (NSCLC) remains unverified. The retrospective study investigated efficacy and safety of camrelizumab...
7.
Wu H, Huang N, Zhao C, Hu X, Da L, Huang W, et al.
Ann Transl Med
. 2022 Apr;
10(6):294.
PMID: 35433955
Background: The timely addition of anlotinib to the nab-paclitaxel/gemcitabine regimen may further increase the treatment efficacy for pancreatic adenocarcinoma (PDAC), which has not yet been reported. Therefore, we aimed to...
8.
Huang N, Zhao C, Hu X, Zhang C, Xiong F, Huang W, et al.
Transl Cancer Res
. 2022 Mar;
11(1):252-261.
PMID: 35261901
Background: Sintilimab is a recombinant fully human anti-programmed death 1 (PD-1) monoclonal antibody that blocks the interaction of PD-1 with its ligand. We evaluated the safety and efficacy of sintilimab...
9.
Bao J, Wu Z, Zhang C, Zhang M, Wang Y, Li H, et al.
Am J Transl Res
. 2022 Feb;
14(1):633-642.
PMID: 35173881
Objective: To explore the efficacy and mechanism of osimertinib combined with bevacizumab in treating postoperative epidermal growth factor receptor (EGFR) positive stage II-IIIA lung adenocarcinoma. Methods: In this retrospective study,...
10.
Liu H, Zhang C
Transl Cancer Res
. 2022 Feb;
9(11):7183-7195.
PMID: 35117322
Background: Hepatocellular carcinoma (HCC) is one of the most life-threatening malignancies worldwide due to the lack of significant improvement in therapeutic methods. This study aimed to unravel the effects of...